补体受体1与疾病和药物的研究进展  

Advances in CR1 and Its Association with Diseases and Drugs

作　　者：陈志远 王东伟[1] 王庆东 Chen Zhiyuan;Wang Dongwei;Wang Qingdong(Department of Anaesthesia,The First Affiliated Hospital of Jiamusi University,Jiamusi 154000,China)

机构地区：[1]佳木斯大学附属第一医院麻醉科,黑龙江佳木斯154000

出　　处：《广东化工》2021年第3期134-135,133,共3页Guangdong Chemical Industry

摘　　要：人C3b/C4b受体(CD35)称为I型补体受体或CR1(Complement recetor 1),是一种多态性糖蛋白[1],广泛分布于红细胞、粒细胞、单核细胞、肥大细胞、滤泡树突状细胞、肾小球足突细胞、B细胞及部分CD4^(+)T细胞[2],但不表达于血小板[3-4]。CR1有着识别、储存、抗原呈递作用,对清除C3b和C4b调理的细菌、病毒和免疫复合物起着决定性的作用,CR1在一些疾病的发生和发展过程中也起着关键的作用,一些药物对CR1也有着一定的影响。本文对人体内CR1的最新研究做一综述。Human C3b/C4b receptor(CD35),known as complement receptor Type I or CR1,is a polymorphic glycoprotein that is widely distributed in red blood cells,granulocytes,monocytes,mast cells,follicular dendritic cells,glomerular podocytes,B cells and some CD4^(+)T cells,but does not express platelets.CR1 plays a decisive role in the elimination of bacteria,viruses and immune complexes regulated by C3b and C4b.CR1 also plays a key role in the occurrence and development of some diseases,and some drugs also have a certain influence on CR1.This article reviews the latest research on CR1 in human.

关 键 词：Ⅰ型补体受体 免疫 疾病 药物 

分 类 号：TQ[化学工程]